Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results released for quarter ended June 30, 2026.
Ginkgo Bioworks Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results released for quarter ended June 30, 2026
- Full financial figures and management commentary contained in Exhibit 99.1
- Investor-relevant disclosures also distributed through SEC filings, calls, websites, blog, and social media
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $20.2M, down 48% from $39.1M, reflecting restructuring-driven program rationalization
- Continuing-operations net loss widened to $57.3M from $53.2M; Adjusted EBITDA loss reached $36.3M versus $25.4M
- Cash, cash equivalents and marketable securities totaled $302M at June 30, supporting 2026 cash-burn guidance of $150M–$125M
- Government-backed autonomous-lab opportunity expanded across MIT, Caltech, Northwestern, Maryland and PNNL’s $47M EMSL project
- ADME-One reportedly priced 10X below WuXi and secured 17 customers in its first six weeks, offering potential commercial traction
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Ginkgo Bioworks Holdings, Inc. 8-K filings
Get the next DNA 8-K as it lands
Follow DNA for push alerts, or ask the research agent what this filing means.